RBD1119
/ Suzhou Ribo
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 28, 2026
Suzhou Ribo Life Science…and Ribocure Pharmaceuticals…announce the submission of Phase 2 Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for RBD1119, a siRNA based therapeutic for the treatment of coronary artery disease (CAD).
(Press Release Hub)
New P2 trial • Coronary Artery Disease
May 09, 2026
Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=32 | Active, not recruiting | Sponsor: Suzhou Ribo Life Science Co. Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed
October 01, 2025
Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=32 | Recruiting | Sponsor: Suzhou Ribo Life Science Co. Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open
June 30, 2025
Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=32 | Not yet recruiting | Sponsor: Suzhou Ribo Life Science Co. Ltd.
New P1 trial
1 to 4
Of
4
Go to page
1